peterschreiber.media H.C.
Wainwright initiated coverage of Vanda Pharmaceuticals ( NASDAQ: VNDA ) with a buy rating, citing its negative enterprise value. The investment bank said its rating was based on Vanda’s well-established product portfolio, a track record of execution, a pipeline of potentially highly accretive programs.